Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

Abstract

In this cohort of refractory CD patients receiving long-term ustekinumab therapy, more than 50% of patients continued ustekinumab treatment with no loss of response, intolerance or surgery and with a good safety profile.